| Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis N Ahmad, SD Ahuja, OW Akkerman, JWC Alffenaar, LF Anderson, ... The Lancet 392 (10150), 821-834, 2018 | 520 | 2018 |
| Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study K Schnippel, N Ndjeka, G Maartens, G Meintjes, I Master, N Ismail, ... The lancet respiratory medicine 6 (9), 699-706, 2018 | 269 | 2018 |
| Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF GJ Churchyard, WS Stevens, LD Mametja, KM McCarthy, V Chihota, ... The Lancet Global Health 3 (8), e450-e457, 2015 | 249 | 2015 |
| MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network GB Migliori, S Tiberi, A Zumla, E Petersen, JM Chakaya, C Wejse, ... International Journal of Infectious Diseases 92, S15-S25, 2020 | 221 | 2020 |
| Tuberculosis control in South Africa: successes, challenges and recommendations: tuberculosis control-Progress towards the Millennium Development Goals GJ Churchyard, LD Mametja, L Mvusi, N Ndjeka, Y Pillay, AC Hesseling, ... South African Medical Journal 104 (3), 244-248, 2014 | 208 | 2014 |
| Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis N Ndjeka, F Conradie, K Schnippel, J Hughes, N Bantubani, H Ferreira, ... The International Journal of Tuberculosis and Lung Disease 19 (8), 979-985, 2015 | 169 | 2015 |
| High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen N Ndjeka, K Schnippel, I Master, G Meintjes, G Maartens, R Romero, ... European Respiratory Journal 52 (6), 2018 | 118 | 2018 |
| Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: a retrospective cohort study H Cox, L Dickson-Hall, N Ndjeka, A van’t Hoog, A Grant, F Cobelens, ... PLoS medicine 14 (2), e1002238, 2017 | 115 | 2017 |
| The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis K Dheda, T Gumbo, G Maartens, KE Dooley, M Murray, J Furin, ... The Lancet Respiratory Medicine 7 (9), 820-826, 2019 | 107 | 2019 |
| Defining bedaquiline susceptibility, resistance, cross-resistance and associated genetic determinants: a retrospective cohort study NA Ismail, SV Omar, L Joseph, N Govender, L Blows, F Ismail, H Koornhof, ... EBioMedicine 28, 136-142, 2018 | 107 | 2018 |
| Standardised shorter regimens versus individualised longer regimens for rifampin-or multidrug-resistant tuberculosis S Abidi, J Achar, MMA Neino, D Bang, A Benedetti, S Brode, JR Campbell, ... European Respiratory Journal 55 (3), 2020 | 70 | 2020 |
| Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa E Sinanovic, L Ramma, A Vassall, V Azevedo, L Wilkinson, N Ndjeka, ... The international journal of tuberculosis and lung disease 19 (2), 172-178, 2015 | 70 | 2015 |
| An all-oral 6-month regimen for multidrug-resistant tuberculosis: a multicenter, randomized controlled clinical trial (the NExT study) A Esmail, S Oelofse, C Lombard, R Perumal, L Mbuthini, ... American Journal of Respiratory and Critical Care Medicine 205 (10), 1214-1227, 2022 | 62 | 2022 |
| Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross … NA Ismail, SV Omar, H Moultrie, Z Bhyat, F Conradie, M Enwerem, ... The Lancet Infectious Diseases 22 (4), 496-506, 2022 | 62 | 2022 |
| Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study M Dryden, C Mudara, C Vika, L Blumberg, N Mayet, C Cohen, S Tempia, ... The Lancet Global Health 10 (9), e1247-e1256, 2022 | 55 | 2022 |
| Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries L Guglielmetti, C Hewison, Z Avaliani, J Hughes, N Kiria, N Lomtadze, ... The International Journal of Tuberculosis and Lung Disease 21 (2), 167-174, 2017 | 51 | 2017 |
| Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort … K Schnippel, K Shearer, D Evans, R Berhanu, N Ndjeka International Journal of Infectious Diseases 39, 89-94, 2015 | 50 | 2015 |
| Clinical access to Bedaquiline Programme for the treatment of drug-resistant tuberculosis F Conradie, G Meintjes, J Hughes, G Maartens, H Ferreira, S Siwendu, ... South African Medical Journal 104 (3), 164-165, 2014 | 47 | 2014 |
| Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South … N Ndjeka, JR Campbell, G Meintjes, G Maartens, HS Schaaf, J Hughes, ... The Lancet Infectious Diseases 22 (7), 1042-1051, 2022 | 43 | 2022 |
| Opportunities from a new disease for an old threat: Extending COVID-19 efforts to address tuberculosis in South Africa M Loveday, H Cox, D Evans, J Furin, N Ndjeka, M Osman, K Naidoo | 41 | 2020 |
